• In April 2026, Compass Therapeutics reported that its Phase 2/3 COMPANION-002 trial in advanced biliary tract cancer met the primary endpoint of overall response rate and a key secondary endpoint of progression-free survival for tovecimig plus paclitaxel versus paclitaxel alone, with no new safety concerns observed.
• An intriguing finding was that patients who crossed over from paclitaxel alone to the tovecimig combination lived longer than those who stayed on paclitaxel, despite initially progressing faster on monotherapy.
• We’ll now look at how these progression-free survival gains with tovecimig may influence Compass Therapeutics’ broader investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Compass Therapeutics' Investment Narrative?

For Compass Therapeutics, being a shareholder means believing that tovecimig can anchor a meaningful oncology franchise despite the company’s zero revenue base, continuing losses and recent share price collapse. The COMPANION-002 data sharpen that thesis: hitting both overall response rate and progression-free survival in second-line biliary tract cancer gives Compass a more concrete clinical asset, even if overall survival remains hard to interpret because of extensive crossover. Near term, the key catalysts now cluster around full data at upcoming conferences, potential regulatory feedback, and clarity on how a small, loss-making biotech funds any next steps after last year’s equity raises. At the same time, the trial’s hypertension and neutropenia rates, plus an inexperienced management team and recent dilution, keep execution and financing risk front and center. However, the funding runway and dilution risk are information investors should really be across.

Despite retreating, Compass Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Two Simply Wall St Community fair value estimates span from about US$11.25 to nearly US$51.90, showing very different expectations. Set that against Compass’s steep share price fall and the fresh COMPANION-002 data, and it is clear you are weighing meaningful clinical proof of concept against ongoing cash burn and funding uncertainty, with many investors reaching very different conclusions.

Explore 2 other fair value estimates on Compass Therapeutics - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Compass Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Compass Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Compass Therapeutics' overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Find 53 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.